STAT5 inhibitors are under development for hematologic cancers, yet our findings suggest that indiscriminate inhibition of STAT5 activity may inadvertently suppress STAT5B’s tumor-suppressive functions in solid tumors. Here, STAT5A is linked to hematopoietic and lymphoid cell neoplasm.